- Opioid defendants have chosen the huge settlement route one after another and the domino effect means Endo is next.
- WSJ has announced that Endo is said to have engaged the consulting firm Alvarez & Marsal Holdings LLC for restructuring.
- As a previous investor in Mallinckrodt, I am getting a sense of deja vu and foresee Endo following the same path to bankruptcy.
- With a weak balance sheet, lingering opioid lawsuits and the upcoming threat of a generic vasopressin competitor, the likelihood of a bankruptcy announcement in the coming months is high.
- I recommend buying long-dated 2023 puts to capitalize on the bankruptcy investment thesis.
For further details see:
Endo International: The End May Be Near